Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

(2016) Yijiang Shi et al.   CANCER RESEARCH

Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

(2016) Zhipeng Zou et al.   CURRENT CANCER DRUG TARGETS

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma

(2016) Brent Holmes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TORC2 Structure and Function

(2016) Christl Gaubitz et al.   TRENDS IN BIOCHEMICAL SCIENCES

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

(2015) Kenta Masui et al.   BRAIN PATHOLOGY

Target of Rapamycin Complex 2 Regulates Actin Polarization and Endocytosis via Multiple Pathways

(2015) Delphine Rispal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

(2015) Kenta Masui et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

(2015) H. Cheng et al.   Cancer Discovery

Chemical Genetics of Rapamycin-Insensitive TORC2 in S. cerevisiae

(2013) Joseph I. Kliegman et al.   Cell Reports

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial–mesenchymal transition (EMT)

(2012) I Serrano et al.   ONCOGENE

Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice

(2012) Tariq Bashir et al.   PLoS One

Glioblastoma: From Molecular Pathology to Targeted Treatment

(2011) Timothy F. Cloughesy et al.   Annual Review of Pathology-Mechanisms of Disease

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?

(2011) T. F. Cloughesy et al.   CLINICAL CANCER RESEARCH

Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma

(2011) C. Cloninger et al.   MOLECULAR CANCER THERAPEUTICS

The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

(2011) Manfred Westphal et al.   NATURE REVIEWS NEUROSCIENCE

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

mTOR Complex Component Rictor Interacts with PKC  and Regulates Cancer Cell Metastasis

(2010) F. Zhang et al.   CANCER RESEARCH

Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction

(2010) Daming Gao et al.   MOLECULAR CELL

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer

(2009) P. Gulhati et al.   CLINICAL CANCER RESEARCH

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

TOR complex 2: a signaling pathway of its own

(2009) Nadine Cybulski et al.   TRENDS IN BIOCHEMICAL SCIENCES

Hsp70 associates with Rictor and is required for mTORC2 formation and activity

(2008) Jheralyn Martin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Rictor-Myo1c Complex Participates in Dynamic Cortical Actin Events in 3T3-L1 Adipocytes

(2008) G. N. Hagan et al.   MOLECULAR AND CELLULAR BIOLOGY